Realize the potential of RNA therapeutics

Design, develop, and characterize novel RNA therapeutics — all on a unified digital platform.
Trusted by the world's leading biotech organizations
Over 200,000 scientists across Fortune 500 companies, startups, and renowned academic institutions are building on Benchling.
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image
Logo Image

RNA Therapeutics R&D Solution

1-Design-oligos.png

Benchling’s RNA Therapeutics Solution was developed in partnership with leading industry innovators. For the first time, R&D teams can design chemically modified oligonucleotides, centralize experimental results, standardize on syntax, and collaborate with teammates more effectively on a single platform. Our modern, digital R&D solution combines the capabilities expected from in silico design tools, ELN, and LIMS into one modern, unified, fully-configurable, and easy-to-use solution that adapts to the rapidly evolving needs of RNA therapeutics R&D.

Simplify collaboration across multidisciplinary teams

Scientists design oligos with intuitive design tools, centralize experimental data, standardize sequence design, and establish a scalable common language across organizations.

Improve data quality and real-time scientific insights

Scientists keep consistent records across experiments, automatically centralize all key results, and aggregate results from diverse assays for real-time visualization in-platform.

Accelerate the speed of the entire RNA therapeutic lifecycle

Scientists and executives quickly track oligo modifications and consequent impact on biological activity to rapidly iterate on oligo candidates with customizable decision support tools.

1-Design-oligos.png
Visualize and modify sequences with an intuitive user interface. Standardize oligo sequence design with HELM and IDT syntax. Automate creation and modification of oligo sequences with REST APIs.
Standardize experimental data capture with results tables. Centralize all sample-relevant results automatically. Visualize analytical results with custom dashboards.
Leverage institutional knowledge across teams with a custom monomer library. Find both natural and chemically modified sequences with search features. Share HELM and IDT notations of oligo sequences with vendors and collaborators.

How we deliver
Dedicated expertise

Our Customer Experience professionals possess deep scientific expertise as well as training on information technology best practices. They apply this know-how to support RNA therapeutic customers across a wide range of R&D teams.

Continuous oversight

Leverage Benchling's pre-implementation solutions consulting, professional implementation services, and customer success management expertise to help you get the most out of Benchling.

Focused R&D support

Take advantage of Benchling’s foundational implementation guides, developed by our Customer Experience team to support many RNA Therapeutic R&D functions.

"At Ribometrix we use specialized technology to identify therapeutically compelling RNAs. As a platform therapeutics company, we create differently modified RNAs for the assays we run. With Benchling, we have manageable uniqueness verification processes that gives our scientists access to the same data."
Katie WarnerVP, RNA Biology, Ribometrix

Join over 200,000 scientists using Benchling to power their biotech R&D

Helix Image